Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Alkermes Profit Plunges Off But Stock Jumps

By Pharmaceutical Processing | July 25, 2013

Irish drugmaker Alkermes PLC’s fiscal-first quarter earnings were down about 67 percent compared to last year, when the Irish drugmaker booked $20 million in intellectual property license revenue.

Alkermes earned $7.3 million, or 5 cents per share, in the three months that ended June 30. That compares to earnings of $22.4 million, or 17 cents per share, in last year’s quarter. Adjusted earnings, which exclude things like depreciation and amortization expenses, totaled 30 cents per share in the latest quarter.

Revenue fell 9 percent to $138.6 million for the company, which is switching from a fiscal year that ends in March to a calendar year that concludes Dec. 31.

Analysts expected, on average, adjusted earnings of 38 cents per share on $151.9 million in revenue, according to FactSet.

The drugmaker actually did better than the 23 cents per share in adjusted earnings that MKM Partners analyst Dr. Jon LeCroy was expecting. He said the company’s operating costs also came in lower than he expected, and the addiction treatment Vivitrol did “extremely well.”

Vivitrol revenue climbed 40 percent to $17.4 million. Manufacturing and royalty revenues from Alkermes’ long-acting atypical antipsychotic franchise climbed 16 percent to $56.2 million.

Total expenses also climbed 4 percent to $125.1 million.

The company’s U.S.-traded shares climbed 4.5 percent, or $1.31, to $30.48 in afternoon trading, while the Nasdaq exchange rose less than 1 percent. Thursday’s gain helped put the stock price up about 65 percent so far this year.

 

 

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE